- Home
- ARWR vs WGS Comparison
ARWR vs WGS Comparison
Compare ARWR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | WGS |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.6B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | ARWR | WGS |
|---|---|---|
| Price | $70.94 | $155.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $60.70 | ★ $130.63 |
| AVG Volume (30 Days) | ★ 3.3M | 458.0K |
| Earning Date | 11-25-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $829,448,000.00 | $402,190,000.00 |
| Revenue This Year | N/A | $41.17 |
| Revenue Next Year | N/A | $23.53 |
| P/E Ratio | ★ N/A | $2,112.76 |
| Revenue Growth | ★ 23258.15 | 50.50 |
| 52 Week Low | $9.57 | $55.17 |
| 52 Week High | $72.36 | $170.87 |
Technical Indicators
Market Signals| Indicator | ARWR | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 78.58 | 57.79 |
| Support Level | $60.29 | $156.17 |
| Resistance Level | $71.50 | $165.62 |
| Average True Range (ATR) | 5.14 | 8.23 |
| MACD | 1.73 | -0.77 |
| Stochastic Oscillator | 95.82 | 59.42 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.